Garoua

Snakebite envenomation is a serious health issue in many developing countries, including sub-Saharan Africa. Researchers are evaluating PANAF-Premium TM, a snake venom antiserum recently introduced by Premium Serums & Vaccines Pvt. Ltd., which has been approved by the WHO for use in this region. This serum targets 24 snake species in Africa and aims to meet local treatment needs where effective antivenoms have been historically scarce. The study is an open-label, Phase IV post-marketing surveillance trial focused on collecting safety and effectiveness data for PANAF-Premium TM in managing snakebites. Participants who have experienced snakebites and show signs of envenomation will be treated according to the standard protocol used in Cameroon, adapted from African Society of Venomology guidelines. The study will closely monitor adverse events, including allergic reactions, and assess the dosage needed for reversing envenomation along with the time required for clinical recovery. There are no restrictions on additional medications or procedures necessary to save the patient, and any serious adverse events will be promptly reported. During the study, participants will be admitted to the hospital and observed for safety and treatment response over 30 days. Researchers will collect epidemiological data about the snake species causing bites, types of envenomation, and patient recovery progress. The study will contribute to national and international safety data on this antivenom. Outcome measures focus on the safety and effectiveness of PANAF-Premium TM within this monitoring period.